$0.87
+0.05 (+5.75%)
Open$0.93
Previous Close$0.83
Day High$0.97
Day Low$0.82
52W High$1.80
52W Low$0.75
Volume—
Avg Volume67.0K
Market Cap13.72M
P/E Ratio—
EPS$-0.80
SectorBiotechnology
Analyst Ratings
Strong Buy
8 analysts
Price Target
+3,787.8% upside
Current
$0.87
$0.87
Target
$33.96
$33.96
$19.62
$33.96 avg
$35.69
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 227.0K | 590.4K | 1.55M |
| Net Income | -31,155,262 | -72,925,190 | 361.3K |
| Profit Margin | -13,700.0% | -13,015.0% | 23.4% |
| EBITDA | -30,891,690 | -76,325,371 | 534.5K |
| Free Cash Flow | — | — | 193.8K |
| Rev Growth | -61.6% | -61.6% | +15.5% |
| Debt/Equity | — | — | 1.22 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $294.45 | -0.18% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $467.06 | -0.22% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $167.95 | -1.05% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $542.62 | -0.81% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $951.19 | -0.86% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $156.65 | -2.00% | 7.7 | 20.98B |